Upstream Bio, Inc.
UPB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002022626
In the last 90 days, Upstream Bio, Inc. insiders filed 0 open-market purchases and 5 sales; 148 institutions reported holding it in 13F filings for Q2 2026, worth $350.1M in total; no superinvestor holds it.
Holders of 5% or more of UPB
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Upstream Bio, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Norges Bank | 13G/A | 7.73%4.21M shares | +2.43 ppfrom 5.30% | Oct 24, 20252 filings | Aug 12, 2026 | SEC |
| FMR LLC | 13G/A | 6.90%3.79M shares | −7.90 ppfrom 14.80% | Nov 7, 20244 filings | Nov 6, 2026 | SEC |
| BlackRock, Inc. | 13G | 5.20%2.81M shares | New | Jul 30, 20261 filing | Jul 30, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
17 Schedule 13D and 13G filings on Upstream Bio, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Nov 6, 20269:45 AM ET | FMR LLCand 1 other | 13G/A | 6.90%3.79M shares | −7.90 ppfrom 14.80% | Oct 30, 2026 | SEC |
| Oct 29, 20264:13 PM ET | Decheng Capital Global Life Sciences Fund IV, L.P.and 2 others | 13G/A | 4.90%2.72M shares | −0.10 ppfrom 5.00%Below 5% | Sep 30, 2026 | SEC |
| Aug 12, 20266:36 AM ET | Norges Bank | 13G/A | 7.73%4.21M shares | +2.43 ppfrom 5.30% | Jun 30, 2026 | SEC |
| Jul 30, 202611:18 AM ET | BlackRock, Inc. | 13G | 5.20%2.81M shares | New | Jun 30, 2026 | SEC |
| May 15, 20264:15 PM ET | Decheng Capital Global Life Sciences Fund IV, L.P.and 4 others | 13G/A | 5.00%2.72M shares | −1.10 ppfrom 6.10% | Mar 31, 2026 | SEC |
| Nov 14, 20254:27 PM ET | TCG Crossover GP I, LLCand 2 others | 13G/A | 3.90%2.12M shares | −1.30 ppfrom 5.20%Below 5% | Sep 30, 2025 | SEC |
| Nov 14, 20254:05 PM ET | HBM Healthcare Investments (Cayman) Ltd. | 13G/A | 4.10%2.20M shares | −1.00 ppfrom 5.10%Below 5% | Sep 30, 2025 | SEC |
| Oct 24, 20254:48 PM ET | Norges Bank | 13G | 5.30%2.88M shares | New | Sep 30, 2025 | SEC |
| Aug 6, 202512:19 PM ET | FMR LLCand 1 other | 13G/A | 14.80%7.94M shares | +1.40 ppfrom 13.40% | Jun 30, 2025 | SEC |
| Feb 14, 20255:38 PM ET | Decheng Capital Global Life Sciences Fund IV, L.P.and 4 others | 13G | 6.10%3.29M shares | New | Dec 31, 2024 | SEC |
| Feb 14, 20254:23 PM ET | TCG Crossover GP I, LLCand 2 others | 13G | 5.20%2.80M shares | New | Dec 31, 2024 | SEC |
| Feb 13, 20254:16 PM ET | HBM Healthcare Investments (Cayman) Ltd. | 13G | 5.10%2.72M shares | New | Dec 31, 2024 | SEC |
| Feb 12, 20259:34 AM ET | FMR LLCand 1 other | 13G/A | 13.40%7.18M shares | – | Dec 31, 2024 | SEC |
| Nov 7, 2024 | FMR LLC | 13GOld format | – | New | – | SEC |
| Oct 22, 2024 | AI Upstream LLC | 13DOld format | – | New | – | SEC |
| Oct 18, 2024 | BCLS Fund III Investments, LP | 13GOld format | – | New | – | SEC |
| Oct 17, 2024 | OrbiMed Advisors LLC | 13DOld format | – | New | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Upstream Bio, Inc. shares.
No Form 144 notices for Upstream Bio, Inc. are on file.